Submission of revised intimation of appointment of additional director.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has submitted a revised intimation to BSE regarding the appointment of Mr. Lakshman Samala (DIN: 10783725) as an Additional Director (Non-Executive Independent), effective February 12, 2025. The original filing on February 12, 2025 had accidentally omitted his detailed profile, which is now being resubmitted as required under SEBI's November 2024 circular. Mr. Samala holds a Ph.D. in Organic Chemistry from the Indian Institute of Chemical Technology and has experience in the pharmaceutical secondary packaging materials industry. He is not related to any existing director, KMP, or promoter of the company, and will hold office until the next general meeting.
This is a procedural compliance update — a routine correction to an earlier filing. No material change for shareholders; it reinforces independent oversight on the board but is unlikely to move the stock price.